Clinical Trials Logo

Bone Metastases clinical trials

View clinical trials related to Bone Metastases.

Filter by:

NCT ID: NCT00104650 Completed - Clinical trials for Bone Metastases in Subjects With Advanced Breast Cancer

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.

NCT ID: NCT00091832 Completed - Breast Cancer Clinical Trials

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.

NCT ID: NCT00040755 Completed - Bone Metastases Clinical Trials

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Start date: May 2002
Phase: Phase 2
Study type: Interventional

BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy

NCT ID: NCT00019695 Terminated - Bone Metastases Clinical Trials

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy